GSA Capital Partners LLP purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 75,175 shares of the company’s stock, valued at approximately $1,613,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Planned Solutions Inc. bought a new position in shares of Kenvue during the fourth quarter valued at $27,000. Mather Group LLC. bought a new position in shares of Kenvue during the first quarter valued at $28,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Kenvue in the 4th quarter worth about $28,000. Oakworth Capital Inc. bought a new stake in Kenvue in the 1st quarter worth about $31,000. Finally, CVA Family Office LLC bought a new stake in Kenvue in the 4th quarter worth about $32,000. 97.64% of the stock is currently owned by institutional investors.
Kenvue Stock Performance
Shares of KVUE stock traded down $0.13 during trading hours on Wednesday, reaching $18.09. 3,169,522 shares of the company traded hands, compared to its average volume of 19,207,486. Kenvue Inc. has a 12-month low of $17.75 and a 12-month high of $25.61. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68. The company has a market cap of $34.64 billion, a P/E ratio of 23.36, a P/E/G ratio of 1.93 and a beta of 1.40. The firm has a 50-day moving average price of $19.08 and a 200 day moving average price of $19.85.
Kenvue Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.42%. Kenvue’s payout ratio is currently 102.56%.
Wall Street Analyst Weigh In
Several research firms recently commented on KVUE. HSBC lifted their price objective on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a report on Wednesday, May 8th. William Blair began coverage on Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating for the company. Citigroup reiterated a “neutral” rating and issued a $21.00 price objective on shares of Kenvue in a report on Tuesday, May 28th. Finally, Sanford C. Bernstein began coverage on Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $23.09.
Get Our Latest Analysis on KVUE
Kenvue Company Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
- Five stocks we like better than Kenvue
- The 3 Best Retail Stocks to Shop for in August
- This Stock’s Price Shifts Into High Gear With Analyst Upgrades
- What is the Dogs of the Dow Strategy? Overview and Examples
- AI Boosts Glass Tech Leader Stock: Shares Up 75% and More to Come
- P/E Ratio Calculation: How to Assess Stocks
- AI Partnership Boosts This Top Tech Stock: Ready for More Gains?
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.